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Abstract 
Immunosuppression, both iatrogenic and disease-related, is associated with a greatly 
increased incidence of cutaneous SCC (cSCC) and with aggressive cSCC and worse disease 
outcomes.  Consequently, rapid access to skin cancer services and prudent surgical choices, 
such as circumferential margin assessment, are essential when treating advanced cSCC in an 
immunosuppressed (IS) patient.  For high-risk cancers and for control of cSCC multiplicity, 
additional strategies should be actively considered within the multidisciplinary clinical care 
team.  These include minimisation or revision of immunosuppressive medications, systemic 
chemoprevention (including retinoids, nicotinamide, capecitabine) and adjuvant therapies 
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such as radiotherapy.  Unfortunately, there is a relative paucity of good evidence for many 
of these treatments in the IS.  Systemic treatments for metastatic cSCC are often 
contraindicated in organ transplant recipients, notably checkpoint inhibitor 
immunotherapy.  There are also toxicity concerns with some conventional chemotherapies 
and EGFR inhibitors.  Until recently, clinical trials have largely excluded immunosuppressed 
individuals. Development of more effective treatment for advanced cSCC in this high-risk 
group and prospective clinical trials are now research priorities. 
 
 
Introduction 
Immunosuppression (IS) is a strong risk factor for the development of cutaneous SCC (cSCC).  
cSCC are frequently multiple and disease-related outcomes are significantly worse in organ 
transplant recipients (OTR) and patients with haematological malignancies1,2,3. Loco-regional 
recurrence is more common4 and a recent national UK study found that IS doubles the risk 
of metastatic cSCC5.  This review will address the specific challenges of managing advanced 
cSCC in the context of immunosuppression, including specific surgical considerations, use of 
radiotherapy as primary and adjuvant treatment, and barriers to use of conventional 
chemotherapies, targeted agents and immunotherapies such as immune checkpoint 
inhibitors (ICI)6,7. Tertiary strategies to reduce risk involving alterations in 
immunosuppressive drugs and chemoprevention will also be outlined. Prospective clinical 
trials are now urgently needed to inform future improvements in treatment choices and 
standards of care.  
 
Surgical Considerations in immunosuppressed patients with advanced cSCC 
Complete surgical resection is central to primary disease control in immunosuppressed 
patients and Mohs surgery or complete circumferential peripheral and deep margin 
assessment is recommended. Certain immunosuppressed patient groups have a higher rate 
of subclinical margin extension, suggesting that Mohs surgery or other intraoperative 
margin assessment may be preferable8,9,10, but this has yet to be tested in a prospective, 
randomised surgical trials. 
 
Limited data exist on the risk of postoperative complications in immunosuppressed patients 
undergoing surgery. Some but not all studies report increased rates of post-operative 
wound infection compared to immunocompetent subjects.  This may be confounded by the 
propensity to put immunosuppressed patients on antibiotic prophylaxis11. Larger, 
prospective studies are needed to determine infection rates and the benefit of prophylaxis, 
if any. 
 
While there is an increased risk of surgical dehiscence in patients on sirolimus12, the 
morbidity associated with skin dehiscence is low enough that most dermatologic surgeons 
will not stop sirolimus for primary skin cancer excision.  Invasive procedures such as 
lymphadenectomy may require transition from sirolimus onto another agent. This needs to 
be balanced against the benefits of switching a patient with cSCC from calcineurin inhibitors 
(CNI) to sirolimus, in order to reduce disease burden. 
 
Thus, significant gaps exist in our understanding of surgical management of 
immunosuppressed patients with advanced cSCC. Future studies should focus on the 
benefits of intraoperative margin assessment in achieving complete clearance, risks of 
postoperative complications and the benefit of prophylactic intervention and postoperative 
adjuvant therapies such as radiotherapy.  
 
Radiotherapy 
Primary radiotherapy is not a first-line option in most OTR with cSCC. OTR tend to be 
younger and more likely to develop multiple tumours at specific anatomic sites, and 
previous radiotherapy to a particular site will usually preclude its subsequent use. 
Nonetheless, radiotherapy is an important strategy where surgery is not feasible or involved 
margins cannot be easily managed surgically.  Death from cSCC usually results from 
uncontrolled loco-regional recurrence which is especially true for immunosuppressed 
individuals who are more likely to develop aggressive cSCC characterised by a high rate of 
loco-regional relapse1. Combined treatment with surgery and radiotherapy is considered 
best practice for patients with cSCC metastatic to lymph nodes13.  There are no prospective 
randomised trials testing the benefit of adjuvant radiotherapy, but retrospective reviews 
consistently report improved disease-free and overall survival in those where surgery was 
combined with adjuvant radiotherapy to the nodal basins.  The worse outcomes in 
immunosuppressed patients mandate a lower threshold for combined surgery and adjuvant 
radiotherapy, although each case should be considered on balance of benefits (reduced 
loco-regional recurrence rate) versus potential carcinogenesis (uncertain risk).   
 
Minimisation of immunosuppression, switch to mTOR inhibitors, systemic retinoids, 
capecitabine and nicotinamide 
Non-surgical strategies to minimize the incidence of cSCC in high-risk OTR include revision of 
immunosuppressive medications and use of chemoprevention. In order to prevent graft 
rejection in OTR, immunosuppressive drug regimens primarily include anti-proliferative 
agents (e.g. mycophenolate mofetil [MMF]), CNI (e.g. tacrolimus, cyclosporine) and 
prednisone14. Reduction or revision of immunosuppressive drugs is generally advised in OTR 
with a history of aggressive or multiple cSCC15. In these high-risk OTR, IS should be 
maintained at the lowest level compatible with adequate graft function16, limiting multi-
drug regimens whenever possible15.  
 
IS also has varying degrees of direct carcinogenic potential. Azathioprine, for example, is 
associated with both an increased incidence and the potential to develop more aggressive 
cSCC in OTR17. Carcinogenic potential of MMF is significantly lower than azathioprine; hence 
transition from azathioprine to MMF is recommended for high-risk patients16.   
 
Another approach to reducing the risk of cSCC in high-risk patients is to transition from a 
CNI to an mTOR inhibitor (sirolimus or everolimus). CNI, through an increase in VEGF and 
TGF-B, can increase the rate of invasion and metastasis16. Although the full immunologic 
sequela of mTOR inhibition is not fully understood, these medications might have 
antineoplastic effects secondary to decreased tumour angiogenesis16. The rate of cSCC in 
patients treated with mTOR inhibitors is significantly reduced compared with calcineurin 
inhibitors. In one study of 120 kidney recipients with a history of at least one cSCC, patients 
treated with sirolimus were significantly less likely to develop cSCC compared to those 
treated with CNI (22% versus 39%, p=0.02)18.  An additional study of 155 kidney recipients 
with a history of at least one cSCC demonstrated a 50% reduction in the rate of cSCC after 
one year19. Both studies had a high rate of drug discontinuation due to adverse effects18,19, 
but doses used in these early studies were arguably too high.  Five-year results show a 
maintained benefit with mTOR inhibition provided the switch was conducted in early, not 
advanced, carcinogenesis20.  
 
Acitretin is the main chemoprophylactic retinoid for OTR at high-risk of SCC. Criteria for 
starting acitretin include multiple cSCCs [e.g. >2-5 per year]; a single cSCC with high 
metastatic risk; or a locally-recurrent or metastatic cSCC. Low-dose acitretin (0.2-0.4 
mg/kg/day for a minimum of 12 months) reduced cSCC development in high-risk OTR in the 
first three years of treatment21. Regimens vary, but acitretin is often started at a low dose 
(e.g. 10 mg every other day) with the dose increased every 4 weeks according to side effects 
until a final dose (e.g. 20-25 mg daily) is reached22. Adverse effects which may limit use or 
result in discontinuation include muco-cutaneous changes such as cheilitis, hair loss and nail 
splitting. Fasting lipids and liver function tests should be checked monthly as the dose is 
increased, and every 3 months once stable and creatinine should be monitored in impaired 
renal function. Life-long treatment is necessary for maintenance of cSCC suppression and 
rebound cSCC development upon discontinuation is well recognised22. 
 
Capecitabine is another option in OTR with multiple cSCC. Capecitabine, a prodrug of 5-
deoxy5-fluorouridine, is enzymatically converted to its active form, 5-fluorouracil in the 
liver23,24.  Low dose capecitabine has been effective in reducing the incidence of cSCC in OTR 
in some case series: for example, capecitabine 0.5 to 1.5 g/m2 was associated with a 68% 
reduction in cSCC per month over one year24. Side effects were diarrhoea, stomatitis, 
neutropenic fever, hand-foot syndrome, and gout15,23. Before treatment, screening for 
dihydropyrimidine dehydrogenase deficiency is required as capecitabine can cause severe 
toxicity in these patients15.  
 
More recently nicotinamide has shown benefit in reducing cSCC risk25. It both reduces UV 
radiation-induced immunosuppression and enhances DNA repair25. It has a favourable 
safety profile and is available over-the-counter25. In a phase III trial of immunocompetent 
individuals, nicotinamide 500mg twice daily reduced the development of cSCC by 30% at 1 
year25.  A phase II trial of 22 kidney recipients suggested a non-significant reduction in new 
cSCC26. An RCT is currently ongoing in Australia.  
 
Conventional chemotherapy and targeted therapy 
Data regarding the use of both conventional chemotherapy and targeted therapy with EGFR 
inhibitors in immunosuppressed individuals are limited. Specific considerations include dose 
adjustments with organ dysfunction, side effects and drug interactions27. For example, 
platinum compounds (e.g. cisplatin, carboplatin) cause myelosuppression and 
nephrotoxicity, and dose adjustments are required in renal impairment. Antimetabolite 
pyrimidine analogues (e.g. 5-fluorouracil, capecitabine) are myelosuppressive, associated 
with coronary artery vasospasm and dose adjustments are needed in liver impairment. 
Taxanes (e.g. paclitaxel) are myelosuppressive, require dose adjustments for liver 
impairment, and caution is required with comcomitant use of CYP3A4 inhibitors/inducers 
(e.g.  antiretrovirals such as ritonavir, saquinavir, nelfinavir and efavirenz) and P-
glycoprotein inhibitors (e.g. CNI, ritonavir and saquinavir). Data on use of anti-EGFR 
inhibitors (e.g. cetuximab) are limited. Although generally well-tolerated, neutropenia, 
infection, liver dysfunction and sudden cardiac arrest27 have been observed. Fatal diffuse 
alveolar damage in two lung transplant recipients on cetuximab, necessitate the use of EGFR 
inhibitors with extreme caution in this group28. 
 
Immunotherapy 
Use of checkpoint inhibitor immmunotherapy for immunosuppressed patients with 
advanced cSCC are restricted to case reports and case series6. Specific considerations 
include the potential risk of graft rejection; relevant immune-related adverse events on 
graft function, e.g. acute interstitial nephritis; possible reduced anti-tumour activity in the 
presence of immunosuppressive drugs and HIV; and effects on replication of HIV and 
hepatitis B/C viruses. Recent evidence - much of it from experience in advanced melanoma - 
suggests that the PD-1/PD-L1 axis is critical for maintaining organ tolerance whereas CTLA-4 
blockade after induction of graft tolerance does not appear to affect allograft survival and 
this is reflected in rates of graft rejection which may be higher with anti PD-1/PD-L1 
immunotherapy6,7,29,30. Although limited data in melanoma also suggest rates of response 
may be comparable in OTRs and immunocompetent individuals, the contribution to graft 
rejection of reduction of immunosuppression in this context has been raised29.  Clinical trials 
are urgently required.  
 
Retransplantation 
Recent evidence suggests that the risk of cSCC increases with retransplantation, and these 
cSCC may be aggressive and associated with high mortality. In a multicentre retrospective 
study of 53 patients with previous post-transplant cSCC who received a second transplant, 
further cSCC developed in 74% of OTR after retransplantation. A higher proportion of these 
cSCC were histologically aggressive (26.4% versus 9.4% after the first transplant), and 
metastatic cSCC occurred in 10 patients of whom 5 died. Contributing to this risk were the 
older age and increased duration of IS, both known risk factors for aggressive SCC, and also 
use of azathioprine and T-cell depleting antibodies. Conversely, five patients in this series 
were retransplanted after an aggressive SCC, and this did not recur after the second 
transplantation suggesting that a history of aggressive SCC may not necessarily preclude 
retransplantation31.  
 
Conclusions 
Advanced cSCC are more frequent and more challenging to treat in immunosuppressed 
patients.  Furthermore, this is an area with very few robust data to guide decision-making.  
Consequently, consensus and sharing of best practice underpin current treatment strategies 
in this context. Alternatives to checkpoint inhibitors are required for OTR and this needs to 
become an area of active scientific and clinical endeavour.  In the meantime, the mainstay 
of management must be prevention, including patient education, photoprotection, skin 
surveillance and aggressive treatment of pre-cancerous actinic keratoses and field 
cancerisation. 
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